Co-occurrence of thyroid and breast cancer is associated with an increased oncogenic SNP burden - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34130653/
Our findings are compatible with the hypothesis of genetic predisposition in the co-occurrence of breast and thyroid cancer. Further exploration of the underlying genetic mechanisms may help in the identification...
Tailoring Therapy to Be Just Right in HER2-Positive Early-Stage Breast Cancer: The Goldilocks Problem
Source : https://ascopubs.org/doi/10.1200/OP.21.00125
Treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer was transformed when pharmacologic targeting of the HER2 oncoprotein became possible, marked by the approval of trastuzumab in 1998....
-
Naveed Saleh, MD, MS – Skipta Team5yrKey Points • In the current commentary from JCO Oncology Practice, authors reviewed recent advances in the treatment of HER2-positive including the utilization of escalation strategies in high-risk patients and de-escalation Show More
![[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors - PubMed](https://static-content-prd.skipta.com/public/skipta/skipta-post/2023-02/pubmed-meta-image_341.png "[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors - PubMed")
[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase Inhibitors - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34102639/
Elevated TLG on early FDG-PET seems to be associated with long-term treatment failure and a poor outcome in patients undergoing CDK4/6 inhibitor therapy for metastatic breast cancer. Early findings indicate...
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34108622/
Molecular alterations in the PI3K/AKT pathway occur frequently in hormone receptor-positive breast tumors. Patients with ER-positive, HER2-negative metastatic breast cancer are often treated with CDK4/6 inhibitors such as palbociclib in...
Time to Completion of Breast Cancer Treatment and Survival - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34105030/
doi: 10.1245/s10434-021-10116-9. Online ahead of print. 1 Breast Surgery, Cleveland Clinic Ohio, 18200 Lorraine Ave, Cleveland, OH, 44111, USA. [email protected]. 2 Cleveland Clinic Ohio, Cleveland, OH, USA. 3 Cleveland Clinic...